Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 5/2017

01-05-2017 | Gynecologic Oncology

Outcome After Sentinel Lymph Node Dissection in Vulvar Cancer: A Subgroup Analysis of the AGO-CaRE-1 Study

Authors: Rüdiger Klapdor, MD, Peter Hillemanns, MD, Linn Wölber, MD, Julia Jückstock, MD, Felix Hilpert, MD, Nikolaus de Gregorio, MD, Severine Iborra, MD, Jalid Sehouli, MD, Anika Habermann, MD, Sophie Teresa Fürst, MD, Hans Georg Strauß, MD, Klaus Baumann, MD, Falk Thiel, MD, Alexander Mustea, MD, Werner Meier, MD, Philipp Harter, MD, Pauline Wimberger, MD, Lars Hanker, MD, Barbara Schmalfeldt, MD, Ulrich Canzler, MD, Tanja Fehm, MD, Alexander Luyten, MD, Martin Hellriegel, MD, Jens Kosse, MD, Christoph Heiss, MD, Peer Hantschmann, MD, Peter Mallmann, MD, Berno Tanner, MD, Jacobus Pfisterer, MD, Barbara Richter, MD, Martin Jäger, MD, Sven Mahner, MD

Published in: Annals of Surgical Oncology | Issue 5/2017

Login to get access

Abstract

Purpose

Analyzing the large patient cohort of the multicenter AGO-CaRE-1 study, we compared isolated sentinel lymph node dissection (SLND) with radical lymph node dissection (LND) of the groin in relation to recurrence rates and survival.

Methods

The AGO-CaRE-1 study retrospectively collected data on treatment patterns and follow-up of vulvar cancer patients [International Federation of Gynecology and Obstetrics (FIGO) stage ≥1B] treated at 29 gynecologic cancer centers between 1998 and 2008. This subgroup analysis evaluated the influence of SLND alone on progression-free survival (PFS) and overall survival (OS).

Results

In 487 (63.1%) of 772 included patients with tumors smaller than 4 cm, an LND was performed and no metastatic lymph nodes were detected (LN0). Another 69/772 (8.9%) women underwent SLND alone, showing a negative SLN (SLN0). Tumors in the LN0 group were larger and showed a deeper invasion (LN0 vs. SLN0 tumor diameter: 20.0 vs. 13.0 mm, p < 0.001; depth of invasion: 4.0 vs. 3.0 mm, p = 0.002). After a median follow-up of 33 months (0–156), no significant differences in relation to isolated groin recurrence rates (SLN0 3.0% vs. LN0 3.4%, p = 0.845) were detected. Similarly, univariate 3-year PFS analysis showed no significant differences between both groups (SLN0 82.7% vs. LN0 77.6%, p = 0.230). A multivariate Cox regression analysis, including tumor diameter, depth of invasion, age, grading, and lymphovascular space invasion was performed: PFS [hazard ratio (HR) 0.970, 95% confidence interval (CI) 0.517–1.821] and OS (HR 0.695, 95% CI 0.261–1.849) did not differ significantly between both cohorts.

Conclusion

This subgroup analysis of the large AGO-CaRE-1 study showed similar results for groin LND and SLND alone with regard to recurrence rates and survival in node-negative patients with tumors <4 cm.
Literature
1.
Levenback C, Burke TW, Gershenson DM, Morris M, Malpica A, Ross MI. Intraoperative lymphatic mapping for vulvar cancer. Obstet Gynecol. 1994;84(2):163–7.PubMed
2.
Gaarenstroom KN, Kenter GG, Trimbos JB, et al. Postoperative complications after vulvectomy and inguinofemoral lymphadenectomy using separate groin incisions. Int J Gynecol Cancer. 2003;13(4):522–7.CrossRefPubMed
3.
Van der Zee, Ate GJ, Oonk MH, De Hullu, Joanne A, et al. Sentinel node dissection is safe in the treatment of early-stage vulvar cancer. J Clin Oncol. 2008;26(6):884–89.CrossRefPubMed
4.
Wills A, Obermair A. A review of complications associated with the surgical treatment of vulvar cancer. Gynecol Oncol. 2013;131(2):467–79.CrossRefPubMed
5.
Burger MP, Hollema H, Emanuels AG, Krans M, Pras E, Bouma J. The importance of the groin node status for the survival of T1 and T2 vulval carcinoma patients. Gynecol Oncol. 1995;57(3):327–34.CrossRefPubMed
6.
te Grootenhuis NC, van der Zee A, van Doorn HC, et al. Sentinel nodes in vulvar cancer: long-term follow-up of the GROningen INternational Study on Sentinel nodes in Vulvar cancer (GROINSS-V) I. Gynecol Oncol. 2016;140(1):8–14.CrossRef
7.
Levenback CF, Ali S, Coleman RL, et al. Lymphatic mapping and sentinel lymph node biopsy in women with squamous cell carcinoma of the vulva: a gynecologic oncology group study. J Clin Oncol. 2012;30(31):3786–91.CrossRefPubMedPubMedCentral
8.
de Hullu JA, Hollema H, Piers DA, et al. Sentinel lymph node procedure is highly accurate in squamous cell carcinoma of the vulva. J Clin Oncol. 2000;18(15):2811–6.CrossRefPubMed
9.
Hampl M, Hantschmann P, Michels W, Hillemanns P. Validation of the accuracy of the sentinel lymph node procedure in patients with vulvar cancer: results of a multicenter study in Germany. Gynecol Oncol. 2008;111(2):282–8.CrossRefPubMed
10.
11.
Hassanzade M, Attaran M, Treglia G, Yousefi Z, Sadeghi R. Lymphatic mapping and sentinel node biopsy in squamous cell carcinoma of the vulva: systematic review and meta-analysis of the literature. Gynecol Oncol. 2013;130(1):237–45.CrossRefPubMed
12.
Mahner S, Jueckstock J, Hilpert F, et al. Adjuvant therapy in lymph node-positive vulvar cancer: the AGO-CaRE-1 Study. J Natl Cancer Inst. 2015;107(3):dju426.
13.
Levenback CF, van der Zee, Ate GJ, Rob L, et al. Sentinel lymph node biopsy in patients with gynecologic cancers. Gynecol Oncol. 2009;114(2):151–6.CrossRefPubMed
14.
Weaver DL, Le UP, Dupuis SL, et al. Metastasis detection in sentinel lymph nodes: comparison of a limited widely spaced (NSABP protocol B-32) and a comprehensive narrowly spaced paraffin block sectioning strategy. Am J Surg Pathol. 2009;33(11):1583–9.CrossRefPubMedPubMedCentral
15.
Robison K, Roque D, McCourt C, et al. Long-term follow-up of vulvar cancer patients evaluated with sentinel lymph node biopsy alone. Gynecol Oncol. 2014;133(3):416–20.CrossRefPubMed
16.
Rodier JF, Janser JC, Routiot T, et al. Sentinel node biopsy in vulvar malignancies: a preliminary feasibility study. Oncol Rep. 1999;6(6):1249–1252.PubMed
17.
Terada KY, Shimizu DM, Jiang CS, Wong JH. Outcomes for patients with T1 squamous cell cancer of the vulva undergoing sentinel node biopsy. Gynecol Oncol. 2006;102(2):200–203.CrossRefPubMed
18.
Moore RG, Robison K, Brown AK, et al. Isolated sentinel lymph node dissection with conservative management in patients with squamous cell carcinoma of the vulva: a prospective trial. Gynecol Oncol. 2008;109(1):65–70.CrossRefPubMed
19.
Covens A, Vella ET, Kennedy EB, Reade CJ, Jimenez W, Le T. Sentinel lymph node biopsy in vulvar cancer: systematic review, meta-analysis and guideline recommendations. Gynecol Oncol. 2015;137(2):351–61.CrossRefPubMed
20.
Puig-Tintore LM, Ordi J, Vidal-Sicart S, et al. Further data on the usefulness of sentinel lymph node identification and ultrastaging in vulvar squamous cell carcinoma. Gynecol Oncol. 2003;88(1):29–34.CrossRefPubMed
21.
Oonk MH, Hollema H, van der Zee AG. Sentinel node biopsy in vulvar cancer: Implications for staging. Best Pract Res Clin Obstet Gynaecol. 2015;29(6):812–21.CrossRefPubMed
22.
Oonk MH, van Hemel BM, Hollema H, et al. Size of sentinel-node metastasis and chances of non-sentinel-node involvement and survival in early stage vulvar cancer: results from GROINSS-V, a multicentre observational study. Lancet Oncol. 2010;11(7):646–52.CrossRefPubMed
Metadata
Title
Outcome After Sentinel Lymph Node Dissection in Vulvar Cancer: A Subgroup Analysis of the AGO-CaRE-1 Study
Authors
Rüdiger Klapdor, MD
Peter Hillemanns, MD
Linn Wölber, MD
Julia Jückstock, MD
Felix Hilpert, MD
Nikolaus de Gregorio, MD
Severine Iborra, MD
Jalid Sehouli, MD
Anika Habermann, MD
Sophie Teresa Fürst, MD
Hans Georg Strauß, MD
Klaus Baumann, MD
Falk Thiel, MD
Alexander Mustea, MD
Werner Meier, MD
Philipp Harter, MD
Pauline Wimberger, MD
Lars Hanker, MD
Barbara Schmalfeldt, MD
Ulrich Canzler, MD
Tanja Fehm, MD
Alexander Luyten, MD
Martin Hellriegel, MD
Jens Kosse, MD
Christoph Heiss, MD
Peer Hantschmann, MD
Peter Mallmann, MD
Berno Tanner, MD
Jacobus Pfisterer, MD
Barbara Richter, MD
Martin Jäger, MD
Sven Mahner, MD
Publication date
01-05-2017
Publisher
Springer International Publishing
Published in
Annals of Surgical Oncology / Issue 5/2017
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-016-5687-0

Other articles of this Issue 5/2017

Annals of Surgical Oncology 5/2017 Go to the issue

Radiation Oncology

Optimal Sequencing of Postmastectomy Radiotherapy and Two Stages of Prosthetic Reconstruction: A Meta-analysis

Breast Oncology

Usefulness of CTC and DTC-BM Detection for Adjuvant Therapy Effects and Prognosis Prediction in Early Breast Carcinoma: Results of 8–11 Years of Follow-up Evaluation

Thoracic Oncology

Is Chemical Pyloroplasty Necessary for Minimally Invasive Esophagectomy?

Endocrine Tumors

The Influence of Preoperative Symptoms on the Death of Patients with Small Intestinal Neuroendocrine Tumors

Hepatobiliary Tumors

Actual 10-Year Survivors After Resection of Hepatocellular Carcinoma

Colorectal Cancer

Microsatellite Instability was not Associated with Survival in Stage III Colon Cancer Treated with Adjuvant Chemotherapy of Oxaliplatin and Infusional 5-Fluorouracil and Leucovorin (FOLFOX)